Cohn K H, Ornstein D L, Wang F, LaPaix F D, Phipps K, Edelsberg C, Zuna R, Mott L A, Dunn J L
Department of Surgery, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756, USA.
Cancer. 1997 Jan 15;79(2):233-44.
A prospective study was initiated to analyze the prognostic value of both the deletion of candidate tumor suppressor genes and the DNA content in colorectal carcinoma specimens.
A prospective study was initiated in 1988, into which 104 patients from the Brooklyn VA Medical Center were accrued through March 1992. DNA restriction endonuclease digests, obtained by the Southern blot technique, were examined for allelic deletions by cDNA probes pnm23-H1 (17q21) YNZ 22.1 (17p13), and p15-65 (18q21). DNA content was measured by image analysis cytometry of Feulgen-stained tumor imprints. Median follow-up was 5.5 years (range, 4-8.5 years).
Patients with nm23-H1 allelic deletions were 3 times as likely to develop distant metastases as patients without nm23-H1 deletions (relative risk [RR], 3.89; 95% confidence interval [CI], 1.39, 10.89). This connection was even stronger after adjustment for TNM stage and site of primary tumor (RR, 5.27; 95% CI, 1.67, 16.68). No significant association of 17p or 18q deletions or ploidy with either distant metastases or overall survival was noted. In multivariate analysis, clinicopathologic variables associated with decreased survival included intracellular mucin production, nuclear grade, TNM stage, and nerve invasion.
A combination of clinicopathologic and molecular biologic variables may identify patients at high risk for death from disseminated colorectal carcinoma.
开展了一项前瞻性研究,以分析候选抑癌基因缺失和结直肠癌标本中DNA含量的预后价值。
1988年启动了一项前瞻性研究,截至1992年3月,共纳入了布鲁克林退伍军人事务医疗中心的104例患者。通过Southern印迹技术获得的DNA限制性内切酶消化产物,用cDNA探针pnm23-H1(17q21)、YNZ 22.1(17p13)和p15-65(18q21)检测等位基因缺失情况。通过对Feulgen染色的肿瘤印片进行图像分析细胞术测量DNA含量。中位随访时间为5.5年(范围4 - 8.5年)。
与无nm23-H1等位基因缺失的患者相比,有nm23-H1等位基因缺失的患者发生远处转移的可能性是前者的3倍(相对危险度[RR],3.89;95%可信区间[CI],1.39,10.89)。在对TNM分期和原发肿瘤部位进行调整后,这种关联更强(RR,5.27;95%CI,1.67,16.68)。未发现17p或18q缺失或倍体与远处转移或总生存期之间存在显著关联。在多变量分析中,与生存期降低相关的临床病理变量包括细胞内粘蛋白产生、核分级、TNM分期和神经侵犯。
临床病理和分子生物学变量相结合,可能有助于识别因播散性结直肠癌而死亡风险较高的患者。